Clinical Trials
29 trialsSymbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Pfizer
Edrecolomab in Treating Patients With Stage II Colon Cancer
National Cancer Institute (NCI)
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
National Cancer Institute (NCI)
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Incyte Corporation
Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
National Cancer Institute (NCI)
KANDLELIT-012
Merck Sharp & Dohme LLC
OPTICAL
Sun Yat-sen University
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
Alliance for Clinical Trials in Oncology
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
Massachusetts General Hospital
KRYSTAL-10
Mirati Therapeutics Inc.
COLOCROSS
Centre Oscar Lambret
Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer
Vejle Hospital
00-046
Memorial Sloan Kettering Cancer Center
DIAMOND
University Hospital, Rouen
ECTX
Kyungpook National University Hospital
Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer
Kyungpook National University Hospital
COnCERTO
University Hospital, Rouen
ID-COMET
Roswell Park Cancer Institute
A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer
Vaccinogen Inc
PICoC
The Royal Wolverhampton Hospitals NHS Trust
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
GlaxoSmithKline
A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer
Qilu Pharmaceutical Co., Ltd.
ETHOS
Norwegian Department of Health and Social Affairs
IROCAS
UNICANCER
RIFIONA
Centre Hospitalier Universitaire, Amiens
FIDURA
Sahlgrenska University Hospital
The Sagittarius Trial
IFOM ETS - The AIRC Institute of Molecular Oncology
Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer
First Affiliated Hospital of Guangxi Medical University
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Pfizer